- Home
- GLXG vs SABS Comparison
GLXG vs SABS Comparison
Compare GLXG & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLXG
- SABS
- Stock Information
- Founded
- GLXG 2013
- SABS 2014
- Country
- GLXG Hong Kong
- SABS United States
- Employees
- GLXG N/A
- SABS N/A
- Industry
- GLXG
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- GLXG
- SABS Health Care
- Exchange
- GLXG NYSE
- SABS Nasdaq
- Market Cap
- GLXG 16.2M
- SABS 19.0M
- IPO Year
- GLXG 2024
- SABS N/A
- Fundamental
- Price
- GLXG $0.89
- SABS $1.63
- Analyst Decision
- GLXG
- SABS Strong Buy
- Analyst Count
- GLXG 0
- SABS 5
- Target Price
- GLXG N/A
- SABS $12.40
- AVG Volume (30 Days)
- GLXG 62.6K
- SABS 75.8K
- Earning Date
- GLXG 03-25-2025
- SABS 03-28-2025
- Dividend Yield
- GLXG N/A
- SABS N/A
- EPS Growth
- GLXG N/A
- SABS N/A
- EPS
- GLXG 0.04
- SABS N/A
- Revenue
- GLXG $3,858,088.00
- SABS $1,512,723.00
- Revenue This Year
- GLXG N/A
- SABS N/A
- Revenue Next Year
- GLXG N/A
- SABS N/A
- P/E Ratio
- GLXG $20.33
- SABS N/A
- Revenue Growth
- GLXG N/A
- SABS N/A
- 52 Week Low
- GLXG $0.70
- SABS $1.45
- 52 Week High
- GLXG $16.93
- SABS $6.30
- Technical
- Relative Strength Index (RSI)
- GLXG N/A
- SABS 38.93
- Support Level
- GLXG N/A
- SABS $1.45
- Resistance Level
- GLXG N/A
- SABS $1.74
- Average True Range (ATR)
- GLXG 0.00
- SABS 0.17
- MACD
- GLXG 0.00
- SABS 0.05
- Stochastic Oscillator
- GLXG 0.00
- SABS 40.27
About GLXG GALAXY PAYROLL GROUP LTD
Galaxy Payroll Group Ltd provides payroll outsourcing, employment, consultancy, and market research services based in Hong Kong. Its client base includes retail, trading, industrial, IT, financial, and professional services industries. Geographically, the company derives maximum revenue from its clients in the People's Republic of China and the rest from Hong Kong, Macau, Taiwan, Japan, Thailand, Singapore, and other countries.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.